Gyre Therapeutics (GYRE) EBT Margin (2016 - 2025)
Historic EBT Margin for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to 24.96%.
- Gyre Therapeutics' EBT Margin rose 95400.0% to 24.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.24%, marking a year-over-year increase of 883400.0%. This contributed to the annual value of 21.95% for FY2024, which is 897900.0% up from last year.
- As of Q3 2025, Gyre Therapeutics' EBT Margin stood at 24.96%, which was up 95400.0% from 8.36% recorded in Q2 2025.
- In the past 5 years, Gyre Therapeutics' EBT Margin registered a high of 45.93% during Q1 2024, and its lowest value of 1830.73% during Q1 2022.
- Its 5-year average for EBT Margin is 424.65%, with a median of 8.36% in 2025.
- Per our database at Business Quant, Gyre Therapeutics' EBT Margin plummeted by -15035900bps in 2021 and then skyrocketed by 18558800bps in 2023.
- Quarter analysis of 5 years shows Gyre Therapeutics' EBT Margin stood at 832.34% in 2021, then soared by 97bps to 22.46% in 2022, then plummeted by -1544bps to 369.38% in 2023, then soared by 101bps to 2.77% in 2024, then surged by 801bps to 24.96% in 2025.
- Its EBT Margin was 24.96% in Q3 2025, compared to 8.36% in Q2 2025 and 21.01% in Q1 2025.